Quick Comparison

NicotineNMN (Nicotinamide Mononucleotide)
Half-Life1-2 hours2-3 minutes in blood (rapidly converted to NAD+). NAD+ half-life: 1-2 hours in tissue
Typical DosageNootropic dose: 1-2 mg via gum, lozenge, or patch. Start with 0.5-1 mg if nicotine-naive. Patch: 7 mg patch cut into quarters (1.75 mg each). Use intermittently (2-3 times per week maximum) to avoid dependence.Standard: 250-1000 mg daily. Sublingual may improve bioavailability by bypassing first-pass metabolism. Take in the morning — NAD+ follows circadian rhythm and morning supplementation aligns with natural peaks. Effects build over weeks.
AdministrationTransdermal (patch), buccal (gum, lozenge), nasal (spray). Avoid smoking and vaping — the delivery method matters for health.Oral (capsules, powder, sublingual). Sublingual may improve bioavailability. Store in cool, dry place.
Research Papers10 papers10 papers
Categories

Mechanism of Action

Nicotine

Nicotine binds to nicotinic acetylcholine receptors (nAChRs), particularly the high-affinity alpha-4-beta-2 subtype predominant in the brain, causing conformational changes that open the cation channel and allow Na+ and Ca2+ influx, depolarizing the neuron. This triggers vesicular release of dopamine (VTA to nucleus accumbens and prefrontal cortex), norepinephrine (locus coeruleus), acetylcholine (basal forebrain), serotonin, and glutamate. Cognitive enhancement comes from increased acetylcholine in the prefrontal cortex and hippocampus (attention, working memory) and dopamine in mesocortical pathways (motivation, executive function). Nicotine upregulates BDNF through nAChR-mediated Ca2+ signaling and CREB activation, and has anti-inflammatory effects via microglial alpha-7 nAChRs. Neuroprotection may involve reduced excitotoxicity and enhanced neuronal survival pathways.

NMN (Nicotinamide Mononucleotide)

NMN is transported into cells via the Slc12a8 transporter (highly expressed in the small intestine and brain) and converted to NAD+ by nicotinamide mononucleotide adenylyltransferases (NMNAT1 in the nucleus, NMNAT2 in axons/Golgi, NMNAT3 in mitochondria). Elevated NAD+ activates the sirtuin family of NAD+-dependent protein deacetylases: SIRT1 deacetylates PGC-1alpha to promote mitochondrial biogenesis, SIRT3 activates superoxide dismutase 2 (SOD2) and isocitrate dehydrogenase 2 (IDH2) for mitochondrial antioxidant defense, and SIRT6 promotes base excision repair of oxidative DNA damage. NAD+ is also consumed by poly(ADP-ribose) polymerases (PARP1/2) during DNA repair — age-related NAD+ depletion impairs PARP function, allowing DNA damage accumulation. In neurons, NAD+ is required for glycolysis (GAPDH cofactor), the TCA cycle, and Complex I of the electron transport chain, directly fueling the enormous ATP demands of synaptic transmission. NAD+ decline with aging (approximately 50% reduction between ages 40-60) reduces all of these processes simultaneously, creating a cascade of mitochondrial dysfunction, impaired DNA repair, and neuroinflammation that NMN supplementation aims to reverse.

Risks & Safety

Nicotine

Common

Nausea, dizziness, hiccups, jaw soreness (gum), skin irritation (patch). Addictive with daily use.

Serious

Cardiovascular strain — increases heart rate and blood pressure. Avoid with cardiovascular disease. Nicotine toxicity at high doses (>60 mg).

Rare

Seizures at toxic doses, severe allergic reactions.

NMN (Nicotinamide Mononucleotide)

Common

Mild flushing, nausea, headache initially.

Serious

Long-term human safety data still limited (first human trials completed 2020-2023). Theoretical concern about promoting cancer growth in existing tumors (NAD+ fuels fast-growing cells).

Rare

Insomnia if taken late.

Full Profiles